Levonorgestrel

Using a levonorgestrel-releasing intrauterine system device to prevent pregnancy increased risk for breast cancer among women living in Denmark aged 15 to 49 years, according to a research letter published in JAMA.

Oral piroxicam administered along with levonorgestrel improved emergency contraception efficacy without increasing the risk for adverse outcomes, according to trial data published in The Lancet.

Levonorgestrel 52 mg IUD reduces blood loss by more than 90% over 6 months among women with severe heavy menstrual bleeding, according to results of a prospective trial published in Obstetrics & Gynecology.

BALTIMORE — Patients with heavy menstrual bleeding who received the levonorgestrel 52 mg intrauterine device experienced significant and rapid decreases in uterine bleeding after placement, a researcher reported here.

The FDA has updated the consumer information leaflet for levonorgestrel 1.5 mg, or Plan B One-Step, to specify that this medication is not an abortifacient and will not affect an existing pregnancy.

Pregnancy rates and continued use of IUDs at 1 year after placement were similar between people using levonorgestrel and copper IUDs, according to data published in the American Journal of Obstetrics & Gynecology.

The FDA approved Medicines360’s Liletta hormonal IUD for up to 8 years of pregnancy prevention, according to a company press release.

A recent insight in JAMA highlighted the factors that physicians should consider when counseling women with CVD on contraception.

Lower-dose IUDs were associated with an increased risk for ectopic pregnancy compared with higher-dose systems, according to a retrospective cohort study published in Obstetrics & Gynecology.

SAN DIEGO — Liletta, a levonorgestrel-releasing intrauterine system, reduced blood loss in people with heavy menstrual bleeding by more than 90%, regardless of BMI and parity, according to phase 3 data presented here.